<DOC>
	<DOCNO>NCT02207218</DOCNO>
	<brief_summary>This study conduct Asia . The aim study evaluate safety efficacy NovoEight® ( recombinant factor VIII ) patient haemophilia A Japan set routine clinical practice .</brief_summary>
	<brief_title>To Investigate Safety Efficacy NovoEight® ( rFVIII ) During Long-term Treatment Haemophilia A Japan</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtain studyrelated activity . Studyrelated activity procedure relate recording data accord protocol Male female patient diagnosis haemophilia A Age range 0 year A decision initiate treatment commercially available NovoEight® make patient/parent physician Known suspect allergy study product ( ) relate product Previous participation study . Participation define informed consent obtain Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>